Bariatric surgery, the most effective current treatment for patients with obesity, can significantly reduce many adult patients’ risks of developing and dying from obesity-related cancers, a new study led by Cleveland Clinic researchers has found.
A dual blockade approach combining the antibody drug conjugate ado-trastuzumab emtansine with the tyrosine kinase inhibitor neratinib shows encouraging results for patients with HER2-positive metastatic breast cancer, according to a recent clinical trial that also identified a clue to the mechanism behind anti-HER2 therapy resistance in some patients.
How did Cleveland Clinic Cancer Center reduce waiting times for cancer treatment by 33% in four years? As a new column in the ASCO Post explains, it started with a change in institutional mindset and a commitment to treat patients like family members.
Researchers have identified quantitative features extracted from MRI images of HER2-positive breast tumors and the tumor environment that may provide cues to patients’ likelihood of response to targeted chemotherapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Scans, stats and blood work provide only a fraction of the information needed to treat cancer patients, says Jame Abraham, MD, Cleveland Clinic’s Director of Breast Oncology. Read his editorial in U.S. News & World Report.
Results of a multi-institutional phase 1b clinical trial show women with metastatic HER2+ breast cancer respond well to the combina-tion of trastuzumab emtansine and neratinib.
Only if you love what you do, says Jame Abraham, MD, Director of the Breast Oncology Program. A healthy work environment is equally as crucial.
This most recent FDA approval is a testament of neratinib’s efficacy in improving disease-free survival in high risk HER2-positive patients after one year of trastuzumab.
Neratinib and T-DM1 combination therapy has been shown safe and effective for women with advanced, HER2-poitive breast cancer. A phase 1B dose escalation trial shows a 56 percent response rate, with 19 percent showing complete response for up to 18 months.
Two new clinical trials are evaluating olaparib therapy for women with metastatic breast cancer and stage II/III breast cancers marked by BRCA1/BRCA2 mutations and other DNA repair pathway defects.